Form 10-Q CATALYST PHARMACEUTICAL For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500 volatile in choppy trading; Mideast deal, SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Catyalyst Pharmaceutical Partners (CPRX) Tops Q2 EPS by 2c
August 14, 2014 8:04 AM EDTCatyalyst Pharmaceutical Partners (NASDAQ: CPRX) reported Q2 EPS of ($0.05), $0.02 better than the analyst estimate of ($0.07).
For earnings history and earnings-related data on Catyalyst Pharmaceutical Partners (CPRX) click here.
... More